Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization.
Cyclosporine (CyA) was incorporated into polycaprolactone nanoparticles (PCL-NP) in order to increase its oral bioavailability and to control drug distribution, thereby potentially reducing its toxicity. Prior to in vivo studies, the carrier was optimized and characterized by using different techniques. Light scattering (LS) and transmission and scanning electron microscopy (TEM and SEM) indicated the NP were spherical in shape with a mean size of approximately 100 nm. The influence of the solvent evaporation conditions and the polymer and drug amounts on CyA incorporation was established in order to optimize drug loading. When acetone and excess water were removed at constant temperature, no aggregation phenomena were observed. A value of 180 mg PCL was the minimum polymer amount necessary to encapsulate 95% of the drug initially added to the preparation. Under these conditions, HPLC analysis revealed that approximately 130 microg CyA per mg PCL were incorporated for a total CyA concentration of 2.5 mg/ml, being part of the drug adsorbed onto the particle surface. No structural changes or instability of the components during NP preparation were detected by gel permeation chromatography (GPC) and differential scanning calorimetry (DSC). However, GPC studies showed a competition between poloxamer and CyA for adsorption onto the carrier. In addition, DSC results suggested that at least part of the drug associated to NP remained in its crystal form. Therefore, CyA-loaded NP were easily manufactured and characterized and allow for the administration of therapeutic drug doses to experimental animals.
Molpeceres
J
J
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Alcalá, Alcalá de Henares (Madrid), Spain. mrosario.aberturas@u.alcala.es
Aberturas
M R
MR
Guzman
M
M
D000818:Animals; D001673:Biodegradation, Environmental; D001682:Biological Availability; D002152:Calorimetry, Differential Scanning; D002214:Capsules / Q000302:isolation & purification*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004339:Drug Compounding / Q000379:methods*; D016503:Drug Delivery Systems; D006801:Humans; D066298:In Vitro Techniques; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D010316:Particle Size; D011091:Polyesters
D002214:Capsules; D011091:Polyesters; C016240:polycaprolactone; D016572:Cyclosporine